Investment Analysts’ Recent Ratings Changes for IRIDEX (IRIX)

Several analysts have recently updated their ratings and price targets for IRIDEX (NASDAQ: IRIX):

  • 5/28/2024 – IRIDEX is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 5/20/2024 – IRIDEX is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 5/15/2024 – IRIDEX had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $2.00 price target on the stock.
  • 5/12/2024 – IRIDEX is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 5/4/2024 – IRIDEX is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 4/26/2024 – IRIDEX is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 4/18/2024 – IRIDEX is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 4/10/2024 – IRIDEX is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 4/2/2024 – IRIDEX is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

IRIDEX Price Performance

NASDAQ IRIX opened at $2.47 on Friday. IRIDEX Co. has a one year low of $1.31 and a one year high of $3.65. The firm has a market cap of $40.14 million, a P/E ratio of -3.69 and a beta of 0.82. The stock’s 50-day moving average is $2.88 and its 200-day moving average is $2.71.

IRIDEX (NASDAQ:IRIXGet Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The medical equipment provider reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.09). IRIDEX had a negative return on equity of 105.42% and a negative net margin of 21.92%. The business had revenue of $11.76 million for the quarter, compared to the consensus estimate of $12.00 million. During the same period in the prior year, the business earned ($0.13) earnings per share. Equities analysts anticipate that IRIDEX Co. will post -0.49 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in IRIDEX stock. Perkins Capital Management Inc. raised its stake in shares of IRIDEX Co. (NASDAQ:IRIXFree Report) by 13.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,300 shares of the medical equipment provider’s stock after acquiring an additional 5,200 shares during the period. Perkins Capital Management Inc. owned about 0.28% of IRIDEX worth $135,000 as of its most recent SEC filing. Institutional investors own 20.10% of the company’s stock.

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.

See Also

Receive News & Ratings for IRIDEX Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX Co and related companies with MarketBeat.com's FREE daily email newsletter.